Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer

Trial Profile

Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Panitumumab
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms VECTITAX
  • Most Recent Events

    • 29 Sep 2015 Interim results presented at the European Cancer Congress 2015
    • 28 Feb 2015 Status changed from recruiting to completed as reported by European Clinical Trial Database.
    • 23 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top